Title: Mainstreaming Addiction Treatment Act of 2019
Policy area: Crime and Law Enforcement

Summary:
Mainstreaming Addiction Treatment Act of 2019
This bill removes the requirement that a health care practitioner apply for a separate waiver through the Drug Enforcement Administration to dispense certain narcotic drugs (e.g., buprenorphine) for maintenance or detoxification treatment (i.e., substance use disorder treatment).
Further, the bill directs the Substance Abuse and Mental Health Services Administration to conduct a national campaign to educate health care practitioners and encourage them to integrate substance use disorder treatment into their practices.

[Congressional Bills 116th Congress]
[From the U.S. Government Publishing Office]
[H.R. 2482 Introduced in House (IH)]

<DOC>






116th CONGRESS
  1st Session
                                H. R. 2482

  To amend section 303(g) of the Controlled Substances Act (21 U.S.C. 
    823(g)) to eliminate the separate registration requirement for 
     dispensing narcotic drugs in schedule III, IV, or V (such as 
  buprenorphine) for maintenance or detoxification treatment, and for 
                            other purposes.


_______________________________________________________________________


                    IN THE HOUSE OF REPRESENTATIVES

                              May 2, 2019

Mr. Tonko (for himself, Mr. Lujan, Mr. Delgado, Mr. Budd, Ms. Stefanik, 
 and Mr. Turner) introduced the following bill; which was referred to 
the Committee on Energy and Commerce, and in addition to the Committees 
 on the Judiciary, and Ways and Means, for a period to be subsequently 
   determined by the Speaker, in each case for consideration of such 
 provisions as fall within the jurisdiction of the committee concerned

_______________________________________________________________________

                                 A BILL


 
  To amend section 303(g) of the Controlled Substances Act (21 U.S.C. 
    823(g)) to eliminate the separate registration requirement for 
     dispensing narcotic drugs in schedule III, IV, or V (such as 
  buprenorphine) for maintenance or detoxification treatment, and for 
                            other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Mainstreaming Addiction Treatment 
Act of 2019''.

SEC. 2. ELIMINATING SEPARATE REGISTRATION REQUIREMENT FOR DISPENSING 
              NARCOTIC DRUGS IN SCHEDULE III, IV, AND V FOR MAINTENANCE 
              OR DETOXIFICATION TREATMENT.

    (a) In General.--Section 303 of the Controlled Substances Act (21 
U.S.C. 823) is amended--
            (1) by striking paragraph (2) of subsection (g); and
            (2) in subsection (g), as amended--
                    (A) by striking ``(g)(1) Except as provided in 
                paragraph (2), practitioners who dispense narcotic 
                drugs to individuals for maintenance treatment or 
                detoxification treatment'' and inserting ``(g) 
                Practitioners who dispense narcotic drugs (other than 
                narcotic drugs in schedule III, IV, or V) to 
                individuals for maintenance treatment or detoxification 
                treatment'';
                    (B) by redesignating subparagraphs (A), (B), and 
                (C) as paragraphs (1), (2), and (3), respectively; and
                    (C) in paragraph (2), as redesignated, by 
                redesignating clauses (i) and (ii) as subparagraphs (A) 
                and (B), respectively.
    (b) Conforming Changes.--
            (1) Subsections (a) and (d)(1) of section 304 of the 
        Controlled Substances Act (21 U.S.C. 824) are amended by 
        striking ``303(g)(1)'' each place it appears and inserting 
        ``303(g)''.
            (2) Section 309A(a)(2) of the Controlled Substances Act (21 
        U.S.C. 829a) is amended--
                    (A) in the matter preceding subparagraph (A), by 
                striking ``the controlled substance is to be 
                administered for the purpose of maintenance or 
                detoxification treatment under section 303(g)(2)'' and 
                inserting ``the controlled substance is a narcotic drug 
                in schedule III, IV, or V to be administered for the 
                purpose of maintenance or detoxification treatment''; 
                and
                    (B) by striking ``and--'' and all that follows 
                through ``is to be administered by injection or 
                implantation;'' and inserting ``and is to be 
                administered by injection or implantation;''.
            (3) Section 520E-4(c) of the Public Health Service Act (42 
        U.S.C. 290bb-36d(c)) is amended by striking ``information on 
        any qualified practitioner that is certified to prescribe 
        medication for opioid dependency under section 303(g)(2)(B) of 
        the Controlled Substances Act'' and inserting ``information on 
        any practitioner who prescribes narcotic drugs in schedule III, 
        IV, or V of section 202 of the Controlled Substances Act for 
        the purpose of maintenance or detoxification treatment''.
            (4) Section 544(a)(3) of the Public Health Service Act (42 
        U.S.C. 290dd-3) is amended by striking ``any practitioner 
        dispensing narcotic drugs pursuant to section 303(g) of the 
        Controlled Substances Act'' and inserting ``any practitioner 
        dispensing narcotic drugs for the purpose of maintenance or 
        detoxification treatment''.
            (5) Section 1833(bb)(3)(B) of the Social Security Act (42 
        U.S.C. 1395l(bb)(3)(B)) is amended by striking ``first receives 
        a waiver under section 303(g) of the Controlled Substances Act 
        on or after January 1, 2019'' and inserting ``first begins 
        prescribing narcotic drugs in schedule III, IV, or V of section 
        202 of the Controlled Substances Act for the purpose of 
        maintenance or detoxification treatment on or after January 1, 
        2019''.
            (6) Section 1834(o)(3)(C)(ii) of the Social Security Act 
        (42 U.S.C. 1395m(o)(3)(C)(ii)) is amended by striking ``first 
        receives a waiver under section 303(g) of the Controlled 
        Substances Act on or after January 1, 2019'' and inserting 
        ``first begins prescribing narcotic drugs in schedule III, IV, 
        or V of section 202 of the Controlled Substances Act for the 
        purpose of maintenance or detoxification treatment on or after 
        January 1, 2019''.
            (7) Section 1866F(c)(3) of the Social Security Act (42 
        U.S.C. 1395cc-6(c)(3)) is amended--
                    (A) in subparagraph (A), by inserting ``and'' at 
                the end;
                    (B) in subparagraph (B), by striking ``; and'' and 
                inserting a period; and
                    (C) by striking subparagraph (C).
            (8) Section 1903(aa)(2)(C) of the Social Security Act (42 
        U.S.C. 1396b(aa)(2)(C)) is amended--
                    (A) in clause (i), by inserting ``and'' at the end; 
                and
                    (B) by striking clause (ii).

SEC. 3. NATIONAL EDUCATION CAMPAIGN.

    (a) In General.--The Secretary of Health and Human Services, acting 
through the Assistant Secretary for Mental Health and Substance Use, 
shall conduct a national campaign to educate practitioners with respect 
to the elimination of the separate registration requirement under 
section 303(g) of the Controlled Substances Act (21 U.S.C. 823(g)), as 
in effect on the day before the date of enactment of this Act, for 
dispensing narcotic drugs in schedule III, IV, and V for maintenance or 
detoxification treatment.
    (b) Required Components.--The national education campaign under 
subsection (a) shall--
            (1) encourage practitioners to integrate substance use 
        treatment into their practices; and
            (2) include education on publicly available educational 
        resources and training modules that can assist practitioners in 
        treating patients with a substance use disorder.
                                 <all>